| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Entera Bio Ltd.
13G
ENTX · M40527109
|
5.1% |
10/30/2026
Event 10/23/2026
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 5.1% | ||||
| VHCP Co-Investment Holdings III, LLC | 5.1% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 5.1% | ||||
| VHCP Management III, LLC | 5.1% | ||||
| VHCP Management EG, LLC | 5.1% | ||||
| Nimish Shah | 5.1% | ||||
| Bong Y. Koh | 5.1% | ||||
|
Lycia Therapeutics, Inc.
13G
55081P100
|
11.9% |
10/30/2026
Event 10/23/2026
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 11.9% | ||||
| VHCP Co-Investment Holdings III, LLC | 11.9% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 11.9% | ||||
| VHCP Management III, LLC | 11.9% | ||||
| VHCP Management EG, LLC | 11.9% | ||||
| Venrock Healthcare Capital Partners XP, L.P. | 11.9% | ||||
| VHCP Management XP, LLC | 11.9% | ||||
| Bong Y. Koh | 11.9% | ||||
| Nimish Shah | 11.9% | ||||
|
Frazier Life Sciences Acquisition Corp. II
13G
G37103101
|
9.0% |
10/27/2026
Event 10/15/2026
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 9.0% | ||||
| VHCP Co-Investment Holdings III, LLC | 9.0% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 9.0% | ||||
| VHCP Management III, LLC | 9.0% | ||||
| VHCP Management EG, LLC | 9.0% | ||||
| Nimish Shah | 9.0% | ||||
| Bong Y. Koh | 9.0% | ||||
|
X4 Pharmaceuticals, Inc.
13G
XFOR · 98420X202
|
5.6% |
9/21/2026
Event 9/14/2026
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 5.6% | ||||
| VHCP Co-Investment Holdings III, LLC | 5.6% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 5.6% | ||||
| VHCP Management III, LLC | 5.6% | ||||
| VHCP Management EG, LLC | 5.6% | ||||
| Nimish Shah | 5.6% | ||||
| Bong Y. Koh | 5.6% | ||||
|
Korsana Biosciences, Inc.
13D
KRSA · 23255M303
|
9.9% |
9/15/2026
Event 9/8/2026
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | ||||
| VHCP Co-Investment Holdings III, LLC | 9.9% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 9.9% | ||||
| Venrock Healthcare Capital Partners XP, L.P. | 9.9% | ||||
| VHCP Management III, LLC | 9.9% | ||||
| VHCP Management EG, LLC | 9.9% | ||||
| VHCP Management XP, LLC | 9.9% | ||||
| Bong Y. Koh | 9.9% | ||||
| Nimish Shah | 9.9% | ||||
|
Apogee Therapeutics, Inc.
13D/A
Amendment 1
APGE · 03770N101
|
0% |
9/8/2026
Event 9/3/2026
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 0% | ||||
| VHCP Co-Investment Holdings III, LLC | 0% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 0% | ||||
| VHCP Management III, LLC | 0% | ||||
| VHCP Management EG, LLC | 0% | ||||
| Bong Y. Koh | 0% | ||||
| Nimish Shah | 0% | ||||
|
Vor Biopharma Inc.
13G/A
Amendment 3
VOR · 929033207
|
9.9% |
8/14/2026
Event 6/30/2026
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | ||||
| VHCP Co-Investment Holdings III, LLC | 9.9% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 9.9% | ||||
| VHCP Management III, LLC | 9.9% | ||||
| VHCP Management EG, LLC | 9.9% | ||||
| Nimish Shah | 9.9% | ||||
| Bong Y. Koh | 9.9% | ||||
|
Tenax Therapeutics, Inc.
13G/A
Amendment 6
TENX · 88032L605
|
4.7% |
8/14/2026
Event 6/30/2026
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 4.7% | ||||
| VHCP Co-Investment Holdings III, LLC | 4.7% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 4.7% | ||||
| VHCP Management III, LLC | 4.7% | ||||
| VHCP Management EG, LLC | 4.7% | ||||
| Nimish Shah | 4.7% | ||||
| Bong Y. Koh | 4.7% | ||||
|
Oruka Therapeutics, Inc.
13G/A
Amendment 4
ORKA · 687604108
|
7.4% |
8/14/2026
Event 6/30/2026
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 7.4% | ||||
| VHCP Co-Investment Holdings III, LLC | 7.4% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 7.4% | ||||
| VHCP Management III, LLC | 7.4% | ||||
| VHCP Management EG, LLC | 7.4% | ||||
| Nimish Shah | 7.4% | ||||
| Bong Y. Koh | 7.4% | ||||
|
KalVista Pharmaceuticals, Inc.
13G/A
Amendment 4
APLT · 03828A101
|
0% |
8/14/2026
Event 6/30/2026
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 0% | ||||
| VHCP Co-Investment Holdings III, LLC | 0% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 0% | ||||
| VHCP Management III, LLC | 0% | ||||
| VHCP Management EG, LLC | 0% | ||||
| Nimish Shah | 0% | ||||
| Bong Y. Koh | 0% | ||||
|
Jade Biosciences, Inc.
13G/A
Amendment 2
JBIO · 008064206
|
8.3% |
8/14/2026
Event 6/30/2026
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 8.3% | ||||
| VHCP Co-Investment Holdings III, LLC | 8.3% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 8.3% | ||||
| VHCP Management III, LLC | 8.3% | ||||
| VHCP Management EG, LLC | 8.3% | ||||
| Nimish Shah | 8.3% | ||||
| Bong Y. Koh | 8.3% | ||||
|
enGene Holdings Inc.
13G/A
Amendment 4
ENGN · 29286M105
|
0% |
8/14/2026
Event 6/30/2026
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 0% | ||||
| VHCP Co-Investment Holdings III, LLC | 0% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 0% | ||||
| VHCP Management III, LLC | 0% | ||||
| VHCP Management EG, LLC | 0% | ||||
| Nimish Shah | 0% | ||||
| Bong Y. Koh | 0% | ||||
|
Artiva Biotherapeutics, Inc.
13G/A
Amendment 1
ARTV · 04317A107
|
4.2% |
8/14/2026
Event 6/30/2026
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 4.2% | ||||
| VHCP Co-Investment Holdings III, LLC | 4.2% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 4.2% | ||||
| VHCP Management III, LLC | 4.2% | ||||
| VHCP Management EG, LLC | 4.2% | ||||
| Nimish Shah | 4.2% | ||||
| Bong Y. Koh | 4.2% | ||||
|
Adlai Nortye Ltd.
13G/A
Amendment 1
ANL · 00704R109
|
4.4% |
8/14/2026
Event 6/30/2026
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 4.4% | ||||
| VHCP Co-Investment Holdings III, LLC | 4.4% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 4.4% | ||||
| VHCP Management III, LLC | 4.4% | ||||
| VHCP Management EG, LLC | 4.4% | ||||
| Nimish Shah | 4.4% | ||||
| Bong Y. Koh | 4.4% | ||||
|
Relmada Therapeutics, Inc.
13G
RLMD · 75955J402
|
6.2% |
6/9/2026
Event 6/2/2026
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 6.2% | ||||
| VHCP Co-Investment Holdings III, LLC | 6.2% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 6.2% | ||||
| VHCP Management III, LLC | 6.2% | ||||
| VHCP Management EG, LLC | 6.2% | ||||
| Nimish Shah | 6.2% | ||||
| Bong Y. Koh | 6.2% | ||||
|
CytomX Therapeutics, Inc.
13G/A
Amendment 2
CTMX · 23284F105
|
4.6% |
5/15/2026
Event 3/31/2026
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 4.6% | ||||
| VHCP Co-Investment Holdings III, LLC | 4.6% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 4.6% | ||||
| VHCP Management III, LLC | 4.6% | ||||
| VHCP Management EG, LLC | 4.6% | ||||
| Nimish Shah | 4.6% | ||||
| Bong Y. Koh | 4.6% | ||||
|
Enliven Therapeutics, Inc.
13G/A
Amendment 4
ELVN · 29337E102
|
2.8% |
5/15/2026
Event 3/31/2026
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 2.8% | ||||
| VHCP Co-Investment Holdings III, LLC | 2.8% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 2.8% | ||||
| VHCP Management III, LLC | 2.8% | ||||
| VHCP Management EG, LLC | 2.8% | ||||
| Nimish Shah | 2.8% | ||||
| Bong Y. Koh | 2.8% | ||||
|
Erasca, Inc.
13G/A
Amendment 1
ERAS · 29479A108
|
5.3% |
5/15/2026
Event 3/31/2026
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 5.3% | ||||
| VHCP Co-Investment Holdings III, LLC | 5.3% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 5.3% | ||||
| VHCP Management III, LLC | 5.3% | ||||
| VHCP Management EG, LLC | 5.3% | ||||
| Nimish Shah | 5.3% | ||||
| Bong Y. Koh | 5.3% | ||||
|
ORIC Pharmaceuticals, Inc.
13G/A
Amendment 2
ORIC · 68622P109
|
4.2% |
5/15/2026
Event 3/31/2026
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 4.2% | ||||
| VHCP Co-Investment Holdings III, LLC | 4.2% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 4.2% | ||||
| VHCP Management III, LLC | 4.2% | ||||
| VHCP Management EG, LLC | 4.2% | ||||
| Nimish Shah | 4.2% | ||||
| Bong Y. Koh | 4.2% | ||||
|
Surrozen, Inc.
13G/A
Amendment 1
SRZN · 86889P208
|
9.9% |
5/15/2026
Event 3/31/2026
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | ||||
| VHCP Co-Investment Holdings III, LLC | 9.9% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 9.9% | ||||
| VHCP Management III, LLC | 9.9% | ||||
| VHCP Management EG, LLC | 9.9% | ||||
| Nimish Shah | 9.9% | ||||
| Bong Y. Koh | 9.9% | ||||
|
Tenax Therapeutics, Inc.
13G/A
Amendment 5
TENX · 88032L605
|
9.9% |
5/15/2026
Event 3/31/2026
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | ||||
| VHCP Co-Investment Holdings III, LLC | 9.9% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 9.9% | ||||
| VHCP Management III, LLC | 9.9% | ||||
| VHCP Management EG, LLC | 9.9% | ||||
| Nimish Shah | 9.9% | ||||
| Bong Y. Koh | 9.9% | ||||
|
Vor Biopharma Inc.
13G/A
Amendment 2
VOR · 929033207
|
9.9% |
5/15/2026
Event 3/31/2026
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | ||||
| VHCP Co-Investment Holdings III, LLC | 9.9% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 9.9% | ||||
| VHCP Management III, LLC | 9.9% | ||||
| VHCP Management EG, LLC | 9.9% | ||||
| Nimish Shah | 9.9% | ||||
| Bong Y. Koh | 9.9% | ||||
|
Zura Bio Limited
13G/A
Amendment 4
ZURA · G9TY5A101
|
9.9% |
5/15/2026
Event 3/31/2026
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | ||||
| VHCP Co-Investment Holdings III, LLC | 9.9% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 9.9% | ||||
| VHCP Management III, LLC | 9.9% | ||||
| VHCP Management EG, LLC | 9.9% | ||||
| Nimish Shah | 9.9% | ||||
| Bong Y. Koh | 9.9% | ||||
|
Achieve Life Sciences, Inc.
13G
ACHV · 004468500
|
5.2% |
4/24/2026
Event 4/17/2026
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 5.2% | ||||
| VHCP Co-Investment Holdings III, LLC | 5.2% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 5.2% | ||||
| VHCP Management III, LLC | 5.2% | ||||
| VHCP Management EG, LLC | 5.2% | ||||
| Nimish Shah | 5.2% | ||||
| Bong Y. Koh | 5.2% | ||||
|
Korro Bio, Inc.
13G
KRRO · 500946108
|
9.9% |
3/17/2026
Event 3/10/2026
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | ||||
| VHCP Co-Investment Holdings III, LLC | 9.9% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 9.9% | ||||
| VHCP Management III, LLC | 9.9% | ||||
| VHCP Management EG, LLC | 9.9% | ||||
| Nimish Shah | 9.9% | ||||
| Bong Y. Koh | 9.9% | ||||
|
Galecto, Inc.
13G
DMRA · 36322Q206
|
6.0% |
2/17/2026
Event 2/9/2026
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 6.0% | ||||
| VHCP Co-Investment Holdings III, LLC | 6.0% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 6.0% | ||||
| VHCP Management III, LLC | 6.0% | ||||
| VHCP Management EG, LLC | 6.0% | ||||
| Nimish Shah | 6.0% | ||||
| Bong Y. Koh | 6.0% | ||||
|
Vor Biopharma Inc.
13G/A
Amendment 1
VOR · 929033207
|
9.9% |
2/17/2026
Event 12/31/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | ||||
| VHCP Co-Investment Holdings III, LLC | 9.9% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 9.9% | ||||
| VHCP Management III, LLC | 9.9% | ||||
| VHCP Management EG, LLC | 9.9% | ||||
| Nimish Shah | 9.9% | ||||
| Bong Y. Koh | 9.9% | ||||
|
Tenax Therapeutics, Inc.
13G/A
Amendment 4
TENX · 88032L605
|
9.9% |
2/17/2026
Event 12/31/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | ||||
| VHCP Co-Investment Holdings III, LLC | 9.9% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 9.9% | ||||
| VHCP Management III, LLC | 9.9% | ||||
| VHCP Management EG, LLC | 9.9% | ||||
| Nimish Shah | 9.9% | ||||
| Bong Y. Koh | 9.9% | ||||
|
Savara Inc.
13G/A
Amendment 2
SVRA · 805111101
|
9.9% |
2/17/2026
Event 12/31/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | ||||
| VHCP Co-Investment Holdings III, LLC | 9.9% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 9.9% | ||||
| VHCP Management III, LLC | 9.9% | ||||
| VHCP Management EG, LLC | 9.9% | ||||
| Nimish Shah | 9.9% | ||||
| Bong Y. Koh | 9.9% | ||||
|
Perceptive Capital Solutions Corp
13G/A
Amendment 1
PCSC · G70077105
|
0% |
2/17/2026
Event 12/31/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 0% | ||||
| VHCP Co-Investment Holdings III, LLC | 0% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 0% | ||||
| VHCP Management III, LLC | 0% | ||||
| VHCP Management EG, LLC | 0% | ||||
| Nimish Shah | 0% | ||||
| Bong Y. Koh | 0% | ||||
|
ORIC Pharmaceuticals, Inc.
13G/A
Amendment 1
ORIC · 68622P109
|
5.8% |
2/17/2026
Event 12/31/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 5.8% | ||||
| VHCP Co-Investment Holdings III, LLC | 5.8% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 5.8% | ||||
| VHCP Management III, LLC | 5.8% | ||||
| VHCP Management EG, LLC | 5.8% | ||||
| Nimish Shah | 5.8% | ||||
| Bong Y. Koh | 5.8% | ||||
|
Ocular Therapeutix Inc
13G/A
Amendment 3
OCUL · 67576A100
|
3.2% |
2/17/2026
Event 12/31/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 3.2% | ||||
| VHCP Co-Investment Holdings III, LLC | 3.2% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 3.2% | ||||
| VHCP Management III, LLC | 3.2% | ||||
| VHCP Management EG, LLC | 3.2% | ||||
| Nimish Shah | 3.2% | ||||
| Bong Y. Koh | 3.2% | ||||
|
Jade Biosciences, Inc.
13G/A
Amendment 1
JBIO · 008064206
|
9.9% |
2/17/2026
Event 12/31/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | ||||
| VHCP Co-Investment Holdings III, LLC | 9.9% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 9.9% | ||||
| VHCP Management III, LLC | 9.9% | ||||
| VHCP Management EG, LLC | 9.9% | ||||
| Nimish Shah | 9.9% | ||||
| Bong Y. Koh | 9.9% | ||||
|
enGene Holdings Inc.
13G/A
Amendment 3
ENGN · 29286M105
|
7.1% |
2/17/2026
Event 12/31/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 7.1% | ||||
| VHCP Co-Investment Holdings III, LLC | 7.1% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 7.1% | ||||
| VHCP Management III, LLC | 7.1% | ||||
| VHCP Management EG, LLC | 7.1% | ||||
| Nimish Shah | 7.1% | ||||
| Bong Y. Koh | 7.1% | ||||
|
Crescent Biopharma, Inc.
13G/A
Amendment 1
CBIO · G2545C104
|
9.5% |
2/17/2026
Event 12/31/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 9.5% | ||||
| VHCP Co-Investment Holdings III, LLC | 9.5% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 9.5% | ||||
| VHCP Management III, LLC | 9.5% | ||||
| VHCP Management EG, LLC | 9.5% | ||||
| Nimish Shah | 9.5% | ||||
| Bong Y. Koh | 9.5% | ||||
|
CASI Pharmaceuticals, Inc.
13G/A
Amendment 1
CASIF · G1933S101
|
9.2% |
2/17/2026
Event 12/31/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 9.2% | ||||
| VHCP Co-Investment Holdings III, LLC | 9.2% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 9.2% | ||||
| VHCP Management III, LLC | 9.2% | ||||
| VHCP Management EG, LLC | 9.2% | ||||
| Nimish Shah | 9.2% | ||||
| Bong Y. Koh | 9.2% | ||||
|
Adlai Nortye Ltd.
13G
ANL · 00704R109
|
6.1% |
2/11/2026
Event 2/4/2026
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 6.1% | ||||
| VHCP Co-Investment Holdings III, LLC | 6.1% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 6.1% | ||||
| VHCP Management III, LLC | 6.1% | ||||
| VHCP Management EG, LLC | 6.1% | ||||
| Nimish Shah | 6.1% | ||||
| Bong Y. Koh | 6.1% | ||||
|
Century Therapeutics, Inc.
13G
IPSC · 15673T100
|
7.1% |
1/16/2026
Event 1/9/2026
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 7.1% | ||||
| VHCP Co-Investment Holdings III, LLC | 7.1% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 7.1% | ||||
| VHCP Management III, LLC | 7.1% | ||||
| VHCP Management EG, LLC | 7.1% | ||||
| Nimish Shah | 7.1% | ||||
| Bong Y. Koh | 7.1% | ||||
|
Tenax Therapeutics, Inc.
13G/A
Amendment 3
TENX · 88032L605
|
9.9% |
11/14/2025
Event 9/30/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | ||||
| VHCP Co-Investment Holdings III, LLC | 9.9% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 9.9% | ||||
| VHCP Management III, LLC | 9.9% | ||||
| VHCP Management EG, LLC | 9.9% | ||||
| Nimish Shah | 9.9% | ||||
| Bong Y. Koh | 9.9% | ||||
|
Savara Inc.
13G/A
Amendment 1
SVRA · 805111101
|
7.3% |
11/14/2025
Event 9/30/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 7.3% | ||||
| VHCP Co-Investment Holdings III, LLC | 7.3% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 7.3% | ||||
| VHCP Management III, LLC | 7.3% | ||||
| VHCP Management EG, LLC | 7.3% | ||||
| Nimish Shah | 7.3% | ||||
| Bong Y. Koh | 7.3% | ||||
|
Oruka Therapeutics, Inc.
13G/A
Amendment 3
ORKA · 687604108
|
9.9% |
11/14/2025
Event 9/30/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | ||||
| VHCP Co-Investment Holdings III, LLC | 9.9% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 9.9% | ||||
| VHCP Management III, LLC | 9.9% | ||||
| VHCP Management EG, LLC | 9.9% | ||||
| Nimish Shah | 9.9% | ||||
| Bong Y. Koh | 9.9% | ||||
|
Ocular Therapeutix Inc
13G/A
Amendment 2
OCUL · 67576A100
|
7.3% |
11/14/2025
Event 9/30/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 7.3% | ||||
| VHCP Co-Investment Holdings III, LLC | 7.3% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 7.3% | ||||
| VHCP Management III, LLC | 7.3% | ||||
| VHCP Management EG, LLC | 7.3% | ||||
| Nimish Shah | 7.3% | ||||
| Bong Y. Koh | 7.3% | ||||
|
Enliven Therapeutics, Inc.
13G/A
Amendment 3
ELVN · 29337E102
|
5.4% |
11/14/2025
Event 9/30/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 5.4% | ||||
| VHCP Co-Investment Holdings III, LLC | 5.4% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 5.4% | ||||
| VHCP Management III, LLC | 5.4% | ||||
| VHCP Management EG, LLC | 5.4% | ||||
| Nimish Shah | 5.4% | ||||
| Bong Y. Koh | 5.4% | ||||
|
CytomX Therapeutics, Inc.
13G/A
Amendment 1
CTMX · 23284F105
|
9.4% |
11/14/2025
Event 9/30/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 9.4% | ||||
| VHCP Co-Investment Holdings III, LLC | 9.4% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 9.4% | ||||
| VHCP Management III, LLC | 9.4% | ||||
| VHCP Management EG, LLC | 9.4% | ||||
| Nimish Shah | 9.4% | ||||
| Bong Y. Koh | 9.4% | ||||
|
Abivax SA
13G/A
Amendment 2
ABVX · 00370M103
|
0.8% |
11/14/2025
Event 9/30/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 0.8% | ||||
| VHCP Co-Investment Holdings III, LLC | 0.8% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 0.8% | ||||
| VHCP Management III, LLC | 0.8% | ||||
| VHCP Management EG, LLC | 0.8% | ||||
| Nimish Shah | 0.8% | ||||
| Bong Y. Koh | 0.8% | ||||
|
Cybin Inc.
13G
HELP · 23256X407
|
9.9% |
11/7/2025
Event 10/31/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | ||||
| VHCP Co-Investment Holdings III, LLC | 9.9% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 9.9% | ||||
| VHCP Management III, LLC | 9.9% | ||||
| VHCP Management EG, LLC | 9.9% | ||||
| Nimish Shah | 9.9% | ||||
| Bong Y. Koh | 9.9% | ||||
|
Vor Biopharma Inc.
13G
VOR · 929033207
|
9.9% |
9/25/2025
Event 9/18/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | ||||
| VHCP Co-Investment Holdings III, LLC | 9.9% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 9.9% | ||||
| VHCP Management III, LLC | 9.9% | ||||
| VHCP Management EG, LLC | 9.9% | ||||
| Nimish Shah | 9.9% | ||||
| Bong Y. Koh | 9.9% | ||||
|
Cidara Therapeutics, Inc.
13G/A
Amendment 2
CDTX · 171757206
|
3.2% |
8/14/2025
Event 6/30/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 3.2% | ||||
| VHCP Co-Investment Holdings III, LLC | 3.2% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 3.2% | ||||
| VHCP Management III, LLC | 3.2% | ||||
| VHCP Management EG, LLC | 3.2% | ||||
| Nimish Shah | 3.2% | ||||
| Bong Y. Koh | 3.2% | ||||
|
Dianthus Therapeutics, Inc.
13G/A
Amendment 2
DNTH · 252828108
|
3.1% |
8/14/2025
Event 6/30/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 3.1% | ||||
| VHCP Co-Investment Holdings III, LLC | 3.1% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 3.1% | ||||
| VHCP Management III, LLC | 3.1% | ||||
| VHCP Management EG, LLC | 3.1% | ||||
| Nimish Shah | 3.1% | ||||
| Bong Y. Koh | 3.1% | ||||
|
Pharvaris N.V.
13G/A
Amendment 2
PHVS · N69605108
|
3.8% |
8/14/2025
Event 6/30/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 3.8% | ||||
| VHCP Co-Investment Holdings III, LLC | 3.8% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 3.8% | ||||
| VHCP Management III, LLC | 3.8% | ||||
| VHCP Management EG, LLC | 3.8% | ||||
| Nimish Shah | 3.8% | ||||
| Bong Y. Koh | 3.8% | ||||
|
Tenax Therapeutics, Inc.
13G/A
Amendment 2
CDTX · 171757206
|
9.9% |
8/14/2025
Event 6/30/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | ||||
| VHCP Co-Investment Holdings III, LLC | 9.9% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 9.9% | ||||
| VHCP Management III, LLC | 9.9% | ||||
| VHCP Management EG, LLC | 9.9% | ||||
| Nimish Shah | 9.9% | ||||
| Bong Y. Koh | 9.9% | ||||
|
Zura Bio Limited
13G/A
Amendment 3
ZURA · G9TY5A101
|
9.9% |
8/14/2025
Event 6/30/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | ||||
| VHCP Co-Investment Holdings III, LLC | 9.9% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 9.9% | ||||
| VHCP Management III, LLC | 9.9% | ||||
| VHCP Management EG, LLC | 9.9% | ||||
| Nimish Shah | 9.9% | ||||
| Bong Y. Koh | 9.9% | ||||
|
Savara Inc.
13G
SVRA · 805111101
|
5.2% |
7/8/2025
Event 6/30/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 5.2% | ||||
| VHCP Co-Investment Holdings III, LLC | 5.2% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 5.2% | ||||
| VHCP Management III, LLC | 5.2% | ||||
| VHCP Management EG, LLC | 5.2% | ||||
| Nimish Shah | 5.2% | ||||
| Bong Y. Koh | 5.2% | ||||
|
Crescent Biopharma, Inc.
13G
CBIO · 38000Q201
|
9.9% |
6/23/2025
Event 6/13/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | ||||
| VHCP Co-Investment Holdings III, LLC | 9.9% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 9.9% | ||||
| VHCP Management III, LLC | 9.9% | ||||
| VHCP Management EG, LLC | 9.9% | ||||
| Nimish Shah | 9.9% | ||||
| Bong Y. Koh | 9.9% | ||||
|
ORIC Pharmaceuticals, Inc.
13G
ORIC · 68622P109
|
7.7% |
5/30/2025
Event 4/8/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 7.7% | ||||
| VHCP Co-Investment Holdings III, LLC | 7.7% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 7.7% | ||||
| VHCP Management III, LLC | 7.7% | ||||
| VHCP Management EG, LLC | 7.7% | ||||
| Nimish Shah | 7.7% | ||||
| Bong Y Koh | 7.7% | ||||
|
CytomX Therapeutics, Inc.
13G
CTMX · 23284F105
|
8.2% |
5/20/2025
Event 5/13/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 8.2% | ||||
| VHCP Co-Investment Holdings III, LLC | 8.2% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 8.2% | ||||
| VHCP Management III, LLC | 8.2% | ||||
| VHCP Management EG, LLC | 8.2% | ||||
| Nimish Shah | 8.2% | ||||
| Bong Y Koh | 8.2% | ||||
|
Mersana Therapeutics, Inc.
13G/A
Amendment 3
MRSN · 59045L106
|
2.9% |
5/15/2025
Event 3/31/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 2.9% | ||||
| VHCP Co-Investment Holdings III, LLC | 2.9% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 2.9% | ||||
| VHCP Management III, LLC | 2.9% | ||||
| VHCP Management EG, LLC | 2.9% | ||||
| Nimish Shah | 2.9% | ||||
| Bong Y Koh | 2.9% | ||||
|
Cidara Therapeutics, Inc.
13G/A
Amendment 1
CDTX · 171757206
|
9.9% |
5/15/2025
Event 3/31/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | ||||
| VHCP Co-Investment Holdings III, LLC | 9.9% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 9.9% | ||||
| VHCP Management III, LLC | 9.9% | ||||
| VHCP Management EG, LLC | 9.9% | ||||
| Nimish Shah | 9.9% | ||||
| Bong Y Koh | 9.9% | ||||
|
ORIC Pharmaceuticals, Inc.
13G/A
Amendment 1
ORIC · 68622P109
|
4.5% |
5/15/2025
Event 3/31/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 4.5% | ||||
| VHCP Co-Investment Holdings III, LLC | 4.5% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 4.5% | ||||
| VHCP Management III, LLC | 4.5% | ||||
| VHCP Management EG, LLC | 4.5% | ||||
| Nimish Shah | 4.5% | ||||
| Bong Y Koh | 4.5% | ||||
|
Applied Therapeutics, Inc.
13G/A
Amendment 4
APLT · 03828A101
|
4.1% |
5/15/2025
Event 3/31/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 4.1% | ||||
| VHCP Co-Investment Holdings III, LLC | 4.1% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 4.1% | ||||
| VHCP Management III, LLC | 4.1% | ||||
| VHCP Management EG, LLC | 4.1% | ||||
| Nimish Shah | 4.1% | ||||
| Bong Y Koh | 4.1% | ||||
|
Praxis Precision Medicines, Inc.
13G/A
Amendment 4
PRAX · 74006W207
|
4.9% |
5/15/2025
Event 3/31/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 4.9% | ||||
| VHCP Co-Investment Holdings III, LLC | 4.9% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 4.9% | ||||
| VHCP Management III, LLC | 4.9% | ||||
| VHCP Management EG, LLC | 4.9% | ||||
| Nimish Shah | 4.9% | ||||
| Bong Y Koh | 4.9% | ||||
|
Tenax Therapeutics, Inc.
13G/A
Amendment 1
CDTX · 171757206
|
9.9% |
5/15/2025
Event 3/31/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | ||||
| VHCP Co-Investment Holdings III, LLC | 9.9% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 9.9% | ||||
| VHCP Management III, LLC | 9.9% | ||||
| VHCP Management EG, LLC | 9.9% | ||||
| Nimish Shah | 9.9% | ||||
| Bong Y Koh | 9.9% | ||||
|
4D Molecular Therapeutics, Inc.
13G/A
Amendment 3
FDMT · 35104E100
|
1.5% |
5/15/2025
Event 3/31/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 1.5% | ||||
| VHCP Co-Investment Holdings III, LLC | 1.5% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 1.5% | ||||
| VHCP Management III, LLC | 1.5% | ||||
| VHCP Management EG, LLC | 1.5% | ||||
| Nimish Shah | 1.5% | ||||
| Bong Y Koh | 1.5% | ||||
|
Zura Bio Limited
13G/A
Amendment 2
ZURA · G9TY5A101
|
9.9% |
5/15/2025
Event 3/31/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | ||||
| VHCP Co-Investment Holdings III, LLC | 9.9% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 9.9% | ||||
| VHCP Management III, LLC | 9.9% | ||||
| VHCP Management EG, LLC | 9.9% | ||||
| Nimish Shah | 9.9% | ||||
| Bong Y Koh | 9.9% | ||||
|
Jade Biosciences, Inc.
13G
JBIO · 008064206
|
9.9% |
5/5/2025
Event 4/28/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | ||||
| VHCP Co-Investment Holdings III, LLC | 9.9% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 9.9% | ||||
| VHCP Management III, LLC | 9.9% | ||||
| VHCP Management EG, LLC | 9.9% | ||||
| Nimish Shah | 9.9% | ||||
| Bong Y Koh | 9.9% | ||||
|
Surrozen, Inc.
13G
SRZN · 86889P208
|
9.9% |
4/2/2025
Event 3/26/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | ||||
| VHCP Co-Investment Holdings III, LLC | 9.9% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 9.9% | ||||
| VHCP Management III, LLC | 9.9% | ||||
| VHCP Management EG, LLC | 9.9% | ||||
| Nimish Shah | 9.9% | ||||
| Bong Y Koh | 9.9% | ||||
|
Oruka Therapeutics, Inc.
13G/A
Amendment 2
ORKA · 687604108
|
11.1% |
2/27/2025
Event 2/10/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 11.1% | ||||
| VHCP Co-Investment Holdings III, LLC | 11.1% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 11.1% | ||||
| VHCP Management III, LLC | 11.1% | ||||
| VHCP Management EG, LLC | 11.1% | ||||
| Nimish Shah | 11.1% | ||||
| Bong Y Koh | 11.1% | ||||
|
Mersana Therapeutics, Inc.
13G/A
Amendment 2
MRSN · 59045L106
|
8.3% |
2/14/2025
Event 12/31/2024
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 8.3% | ||||
| VHCP Co-Investment Holdings III, LLC | 8.3% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 8.3% | ||||
| VHCP Management III, LLC | 8.3% | ||||
| VHCP Management EG, LLC | 8.3% | ||||
| Nimish Shah | 8.3% | ||||
| Bong Y Koh | 8.3% | ||||
|
enGene Holdings Inc.
13G/A
Amendment 2
ENGN · 29286M105
|
9.9% |
2/14/2025
Event 12/31/2024
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | ||||
| VHCP Co-Investment Holdings III, LLC | 9.9% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 9.9% | ||||
| VHCP Management III, LLC | 9.9% | ||||
| VHCP Management EG, LLC | 9.9% | ||||
| Nimish Shah | 9.9% | ||||
| Bong Y Koh | 9.9% | ||||
|
Century Therapeutics, Inc.
13G/A
Amendment 2
IPSC · 15673T100
|
4.7% |
2/14/2025
Event 12/31/2024
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 4.7% | ||||
| VHCP Co-Investment Holdings III, LLC | 4.7% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 4.7% | ||||
| VHCP Management III, LLC | 4.7% | ||||
| VHCP Management EG, LLC | 4.7% | ||||
| Nimish Shah | 4.7% | ||||
| Bong Y Koh | 4.7% | ||||
|
Astria Therapeutics, Inc.
13G/A
Amendment 2
ATXS · 04635X102
|
4.4% |
2/14/2025
Event 12/31/2024
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 4.4% | ||||
| VHCP Co-Investment Holdings III, LLC | 4.4% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 4.4% | ||||
| VHCP Management III, LLC | 4.4% | ||||
| VHCP Management EG, LLC | 4.4% | ||||
| Nimish Shah | 4.4% | ||||
| Bong Y Koh | 4.4% | ||||
|
Aquestive Therapeutics, Inc.
13G/A
Amendment 1
AQST · 03843E104
|
2.9% |
2/14/2025
Event 12/31/2024
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 2.9% | ||||
| VHCP Co-Investment Holdings III, LLC | 2.9% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 2.9% | ||||
| VHCP Management III, LLC | 2.9% | ||||
| VHCP Management EG, LLC | 2.9% | ||||
| Nimish Shah | 2.9% | ||||
| Bong Y Koh | 2.9% | ||||
|
Applied Therapeutics, Inc.
13G/A
Amendment 3
APLT · 03828A101
|
9.9% |
2/14/2025
Event 12/31/2024
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | ||||
| VHCP Co-Investment Holdings III, LLC | 9.9% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 9.9% | ||||
| VHCP Management III, LLC | 9.9% | ||||
| VHCP Management EG, LLC | 9.9% | ||||
| Nimish Shah | 9.9% | ||||
| Bong Y Koh | 9.9% | ||||
|
Adverum Biotechnologies, Inc.
13G/A
Amendment 2
ADVM · 00773U207
|
0% |
2/14/2025
Event 12/31/2024
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 0% | ||||
| VHCP Co-Investment Holdings III, LLC | 0% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 0% | ||||
| VHCP Management III, LLC | 0% | ||||
| VHCP Management EG, LLC | 0% | ||||
| Nimish Shah | 0% | ||||
| Bong Y Koh | 0% | ||||
|
4D Molecular Therapeutics, Inc.
13G/A
Amendment 2
FDMT · 35104E100
|
6.4% |
2/14/2025
Event 12/31/2024
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 6.4% | ||||
| VHCP Co-Investment Holdings III, LLC | 6.4% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 6.4% | ||||
| VHCP Management III, LLC | 6.4% | ||||
| VHCP Management EG, LLC | 6.4% | ||||
| Nimish Shah | 6.4% | ||||
| Bong Y Koh | 6.4% | ||||
|
Praxis Precision Medicines, Inc.
13G/A
Amendment 3
PRAX · 74006W207
|
6.1% |
2/14/2025
Event 12/31/2024
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 6.1% | ||||
| VHCP Co-Investment Holdings III, LLC | 6.1% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 6.1% | ||||
| VHCP Management III, LLC | 6.1% | ||||
| VHCP Management EG, LLC | 6.1% | ||||
| Nimish Shah | 6.1% | ||||
| Bong Y Koh | 6.1% | ||||
|
Spyre Therapeutics, Inc.
13G/A
Amendment 3
SYRE · 00773J202
|
4.6% |
2/14/2025
Event 12/31/2024
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 4.6% | ||||
| VHCP Co-Investment Holdings III, LLC | 4.6% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 4.6% | ||||
| VHCP Management III, LLC | 4.6% | ||||
| VHCP Management EG, LLC | 4.6% | ||||
| Nimish Shah | 4.6% | ||||
| Bong Y Koh | 4.6% | ||||
|
Viridian Therapeutics, Inc.
13G/A
Amendment 5
VRDN · 92790C104
|
4.5% |
2/14/2025
Event 12/31/2024
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 4.5% | ||||
| VHCP Co-Investment Holdings III, LLC | 4.5% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 4.5% | ||||
| VHCP Management III, LLC | 4.5% | ||||
| VHCP Management EG, LLC | 4.5% | ||||
| Nimish Shah | 4.5% | ||||
| Bong Y Koh | 4.5% | ||||
|
Kalvista Pharmaceuticals, Inc.
13G/A
Amendment 3
APLT · 03828A101
|
10.1% |
2/3/2025
Event 1/30/2025
|
|||
| Venrock Healthcare Capital Partners III, L.P. | 10.1% | ||||
| VHCP Co-Investment Holdings III, LLC | 10.1% | ||||
| Venrock Healthcare Capital Partners EG, L.P. | 10.1% | ||||
| VHCP Management III, LLC | 10.1% | ||||
| VHCP Management EG, LLC | 10.1% | ||||
| Nimish Shah | 10.1% | ||||
| Bong Y Koh | 10.1% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.